NASDAQ$BPMC
Blueprint Medicines Corp · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Blueprint Medicines reported first quarter 2022 results.
Blueprint Medicines achieved $23.8 million in AYVAKIT® net product revenues and $62.7 million in total revenues. They are on track to report topline data for the registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in late summer 2022.
- Achieved $23.8 million in AYVAKIT® (avapritinib) net product revenues, and $62.7 million in total revenues
- AYVAKYT® (avapritinib) launch in Germany underway following European Commission approval for advanced SM on March 25
- First patients dosed in BLU-701, BLU-451, and BLU-222 clinical trials; trial cohort initiated for BLU-945 in combination with osimertinib
- On track to report topline data for registration-enabling PIONEER trial of AYVAKIT in non-advanced SM in late summer 2022
Headline financials
Revenue & EPS history
Blueprint Medicines · Revenue · Quarterly
$62.7M
Forward guidance
Blueprint Medicines continues to anticipate approximately $180 to $200 million in total net revenues in 2022, including approximately $115 to $130 million in AYVAKIT net product revenues. The company continues to expect that its existing cash, cash equivalents and investments, together with anticipated future product revenues, will provide sufficient capital to enable the company to achieve a self-sustainable financial profile.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 16 quarterly earnings reports · overlaid with Q1 2022
+2.5%
Avg return
Earnings day
+2.6%
Avg return
5 days after
+6.3%
Avg return
30 days after
68%
27 / 40 earnings
Positive
+24.7%
Q3 2023
Best reaction
-20.7%
Q2 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +10.9% | +11.0% | +13.3% | |
| Q4 2025 | -8.1% | -10.9% | -13.4% | |
| Q3 2025 | +4.9% | +10.2% | +14.0% | |
| Q2 2024 | -10.7% | -14.4% | -11.8% | |
| Q1 2024 | +13.0% | +14.3% | +11.2% | |
| Q4 2023 | +17.5% | +18.9% | +17.9% | |
| Q3 2023 | +24.7% | +34.1% | +55.8% | |
| Q2 2023 | -20.7% | -26.6% | -21.2% | |
| Q1 2023 | +8.4% | +4.5% | +12.1% | |
| Q4 2022 | +5.0% | -1.2% | +2.4% | |
| Q3 2022 | -11.1% | -19.0% | -8.5% | |
| Q2 2022 | +18.0% | +34.7% | +46.0% | |
| Q1 2022 | +5.9% | -4.9% | -4.8% | |
| Q4 2021 | -17.0% | -19.9% | -21.9% | |
| Q3 2021 | +7.9% | +6.4% | -3.1% | |
| Q2 2021 | +6.0% | +3.8% | +13.2% | |
| Q1 2021 | -1.0% | — | — | |
| Q4 2020 | +3.8% | — | — | |
| Q3 2020 | -2.2% | — | — | |
| Q2 2020 | -0.8% | — | — | |
| Q1 2020 | +0.7% | — | — | |
| Q4 2019 | +3.5% | — | — | |
| Q3 2019 | +10.4% | — | — | |
| Q2 2019 | -9.2% | — | — | |
| Q1 2019 | +9.0% | — | — | |
| Q4 2018 | +1.4% | — | — | |
| Q3 2018 | -1.4% | — | — | |
| Q1 2018 | +1.3% | — | — | |
| Q4 2017 | +5.5% | — | — | |
| Q3 2017 | +4.8% | — | — | |
| Q2 2017 | -9.8% | — | — | |
| Q1 2017 | -11.6% | — | — | |
| Q4 2016 | +13.0% | — | — | |
| Q3 2016 | +9.9% | — | — | |
| Q2 2016 | +2.4% | — | — | |
| Q1 2016 | -1.4% | — | — | |
| Q4 2015 | +4.6% | — | — | |
| Q3 2015 | +1.4% | — | — | |
| Q2 2015 | +2.5% | — | — | |
| Q1 2015 | +8.4% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro